Patents Assigned to Wyeth
  • Substituted dihydrophenanthridinesulfonamides
    Patent number: 6894061
    Abstract: This invention provides a compound of formulae (I) or (II) having the structure or a pharmaceutically acceptable salt thereof which are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatiod arthritis.
    Type: Grant
    Filed: November 20, 2003
    Date of Patent: May 17, 2005
    Assignee: Wyeth
    Inventors: Albert John Molinari, Mark Antony Ashwell, Brian Hugh Ridgway, Amedeo Arturo Failli, William Jay Moore
  • Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-Hydroxytryptamine-6 ligands
    Publication number: 20050101596
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of a CNS disorder related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: November 9, 2004
    Publication date: May 12, 2005
    Applicant: Wyeth
    Inventors: Derek Cole, Magda Asselin
  • 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
    Publication number: 20050101780
    Abstract: Compounds of the formula: wherein: n is an integer from 1-3; X is N, CH, provided that when X is N, n is 2 or 3; R is alkyl of 1 to 3 carbon atoms; R1 is 2,4-diCl, 5-OMe; 2,4-diCl; 3,4,5-tri-OMe; 2-Cl, 5-OMe; 2-Me, 5-OMe; 2,4-di-Me; 2,4-diMe-5-OMe, 2,4-diCl, 5-OEt; R2 is alkyl of 1 to 2 carbon atoms, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: November 3, 2004
    Publication date: May 12, 2005
    Applicant: Wyeth
    Inventors: Frank Boschelli, Kim Arndt, Jennifer Golas
  • Methods and compositions for selectin inhibition
    Publication number: 20050101568
    Abstract: The present invention relates to the field of anti-inflammatory substances, and more particularly to novel compounds that act as antagonists of the mammalian adhesion proteins known as selectins. In some embodiments, methods for treating selectin mediated disorders are provided which include administration of compound of Formula I: wherein the constituent variables are defined herein.
    Type: Application
    Filed: November 9, 2004
    Publication date: May 12, 2005
    Applicant: Wyeth
    Inventors: Neelu Kaila, Silvano Debernardo, Kristin Janz, Raymond Camphausen, Patricia Bedard
  • Methods and compositions for selectin inhibition
    Publication number: 20050101569
    Abstract: The present invention relates to the field of anti-inflammatory substances, and more particularly to novel compounds that act as antagonists of the mammalian adhesion proteins known as selectins. In some embodiments, methods for treating selectin mediated disorders are provided which include administration of compound of Formula I: wherein the constituent variables are defined herein.
    Type: Application
    Filed: November 9, 2004
    Publication date: May 12, 2005
    Applicant: Wyeth
    Inventors: Neelu Kaila, Silvano Debernardo, Kristin Janz, Raymond Camphausen, Patricia Bedard, Adrian Huang
  • Advanced route for the synthesis of cPLA2 inhibitors
    Patent number: 6891065
    Abstract: A process for making a compound of formula (I) in which process the compound HC?C—(CH2)n—NH2 is reacted with the compound R1—SO2Cl to produce an intermediate compound, which intermediate compound is then reacted with the compound of formula to produce the compound of formula (I), and compounds produced by the process of this invention. The terms R1, R2, R3, R4 and n have the definitions set forth in the specification.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: May 10, 2005
    Assignee: Wyeth
    Inventors: Yanzhong Wu, Panolil Raveendranath
  • Sustained release pharmaceutical compositions
    Publication number: 20050095292
    Abstract: The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.
    Type: Application
    Filed: October 28, 2004
    Publication date: May 5, 2005
    Applicant: Wyeth
    Inventors: Eric Benjamin, Wendy Dulin, Yanning Lin, Kai Zhuang
  • Substituted sulfonamide-indoles
    Publication number: 20050096377
    Abstract: The present invention relates generally to substituted sulfonamide indoles such as substituted sulfonamide indoles, and methods of using them.
    Type: Application
    Filed: September 23, 2004
    Publication date: May 5, 2005
    Applicant: WYETH
    Inventor: Baihua Hu
  • Novel succinate salt of O-desmethyl-venlafaxine
    Publication number: 20050096479
    Abstract: A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.
    Type: Application
    Filed: November 10, 2004
    Publication date: May 5, 2005
    Applicant: Wyeth
    Inventors: Anthony Hadfield, Syed Shah, Michael Winkley, Karen Sutherland, James Provost, Aeri Park, Rex Shipplett, Brenton Russell, Beat Weber
  • CHARACTERIZATION OF A MEMBRANE ESTROGEN RECEPTOR
    Publication number: 20050096265
    Abstract: Abstract of the Disclosure The present invention discloses the identification of a novel membrane associated estrogen receptor, termed mER. The membrane associated receptor is involved in rapid signal transduction. Amino acid sequences, nucleic acid sequences, vectors, and host cells are also discussed. Additionally, methods of detecting agonists and antagonists for the receptor are disclosed herein.
    Type: Application
    Filed: February 9, 2004
    Publication date: May 5, 2005
    Applicant: Wyeth
    Inventors: Darlene Deecher, Pamela Swiggard, Donald Frail, Lawrence O'Connor
  • Novel human LXRalpha variants
    Publication number: 20050095677
    Abstract: This invention provides novel human LXR? variant polypeptides and nucleic acids encoding such polypeptides. This invention also provides the therapeutic, diagnostic, and research utilities as well as the production of such polynucleotides and polypeptides. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. 37 CFR 1.72(b).
    Type: Application
    Filed: August 18, 2004
    Publication date: May 5, 2005
    Applicant: Wyeth
    Inventors: Qiang-Yuan Liu, Ponnal Nambi
  • 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents
    Publication number: 20050090508
    Abstract: This invention relates to certain 6-[(substituted)phenyl]triazolopyrimidine compounds or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: September 24, 2004
    Publication date: April 28, 2005
    Applicant: Wyeth Holdings Corporation
    Inventors: Nan Zhang, Semiramis Ayral-Kaloustian, Thai Nguyen, Yanzhong Wu, Wei Tong
  • Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl[ethyl} phosphonic acid and esters thereof
    Publication number: 20050090470
    Abstract: The present invention provides methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1 (7)-en-2-yl]ethyl}phosphonic acid, and esters thereof.
    Type: Application
    Filed: October 20, 2004
    Publication date: April 28, 2005
    Applicant: Wyeth
    Inventors: Bogdan Wilk, Galina Vid, Weiguo Liu, Xinxu Shi
  • Phenyl benzisoxazoles as estrogenic agents
    Patent number: 6884814
    Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein, R1, R2, and R3 are as defined in the specification, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: April 26, 2005
    Assignee: Wyeth
    Inventors: Michael S. Malamas, Tam Q. Dinh, Iwan Gunawan, Michael D. Collini, Heather A. Harris, James C. Keith, Jr., Leo M. Albert
  • Process for the synthesis of nacyl-2-amino-4-alkoxy-5-nitrobenzoic acids
    Publication number: 20050085662
    Abstract: The invention claimed herein provides a process to oxidize N-(5-alkoxy-2-methyl-4-nitrophenyl)acetamides to N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids using potassium permanganate in the presence of magnesium sulfate in aqueous sulfolane or aqueous pyridine.
    Type: Application
    Filed: February 5, 2003
    Publication date: April 21, 2005
    Applicant: Wyeth
    Inventors: Scott Duncan, Augustine Osuma, Sylvain Daigneault, Michel Bernatchez
  • Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
    Publication number: 20050085504
    Abstract: Ortho-sulfonamido aryl hydroxamic acids are provided which are useful, inter alia, for the inhibition of matrix metalloproteinases and the treatment of conditions associated with overexpression of MMPs.
    Type: Application
    Filed: November 4, 2004
    Publication date: April 21, 2005
    Applicant: WYETH
    Inventors: Frances Nelson, Arie Zask, James Chen, Dominick Mobilio, Ramaswamy Nilakantan
  • 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands
    Publication number: 20050085481
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: October 12, 2004
    Publication date: April 21, 2005
    Applicant: Wyeth
    Inventors: Ronald Bernotas, Steven Lenicek, Schuyler Antane
  • Azabicyclylmethyl derivatives of 7,8-dihydro-1,6,9,-trioxa-3-aza-cyclopenta[a]naphthalene as 5-ht1a antagonists
    Publication number: 20050085475
    Abstract: Compounds of the formula are useful for treating the cognitive deficits due to aging, stroke, head trauma, Alzheimer's disease or other neurodegenerative diseases, or schizophrenia and are also useful for the treatment of disorders such as anxiety, aggression and stress, and for the control of various physiological phenomena, such eating disorders, disorders of thermoregulation, and sleep and sexual dysfunction.
    Type: Application
    Filed: June 28, 2004
    Publication date: April 21, 2005
    Applicant: WYETH
    Inventors: Gary Stack, Adam Gilbert, Megan Tran
  • Process for the preparation of 1-[cyano(phenyl)methyl]cyclohexanol compounds
    Publication number: 20050080288
    Abstract: Process for the preparation of 1-[cyano(phenyl)methyl]cyclohexanol compounds of general formula (I): in which R1 is hydrogen or (C1-4)alkoxy, and R2 is hydrogen, (C1-4)alkyl or (C1-4)alkoxy, by reacting a compound of general formula (II): in which R1 and R2 are as defined above, with cyclohexanone in the presence of a catalyst, characterized in that this catalyst is selected from the group comprising alkali metal alcoholates, alkaline earth metal alcoholates, aluminium alcoholates and tetrasubstituted ammonium hydroxide.
    Type: Application
    Filed: October 1, 2004
    Publication date: April 14, 2005
    Applicant: Wyeth
    Inventors: Huldreich Trafelet, Hans-Rudolf Marti
  • Substituted benzoxazoles as estrogenic agents
    Publication number: 20050080117
    Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein R1, R2, R2a, R3, R3a, and R4, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 19, 2004
    Publication date: April 14, 2005
    Applicant: Wyeth
    Inventors: Michael Malamas, Robert McDevitt, Iwan Gunawan, Eric Manas, Michael Collini